No abstract

The Horn River Basin of northeastern British Columbia, Canada, contains natural gas in three Devonian shale units. Isopachs, depths, and net-to gross-pay ratios were determined from well logs for the Muskwa, Otter Park, and Evie Shales and then gridded. Pressure gradients were determined from well test and production data and then gridded into a single grid shared between shales. Because grid points were shared between each grid, volumetric and adsorbed gas equations could be integrated into each grid point. Static values or distributions could then be applied to equation variables and Monte Carlo simulations run to determine probabilistic gas in place (GIP) and marketable resources for each grid point, which were then summed for each shale.Grid points for the isopach and depth maps were treated as static values in the equations while net-togross and pressure gradient grid points became most likely values in Beta distributions where end points were assigned using regional low and high values. Most non-mapped variables in the equations were filled with Beta distributions based on typical values in the area and then applied across the basin without any local variations. On each distribution, whether based on mapped or unmapped variables, a second, overlying distribution was applied on a basin scale. This made entire iterations run a full range from pessimistic to optimistic. A few non-mapped variables in the equations were given static values.Recoverable gas resources were estimated by applying a recovery factor to free GIP estimates. Recoverable volumes from adsorbed GIP estimates were determined from a recovery factor applied to the portion of gas that would desorb during production as pressure decreased to the assumed well abandonment pressure. To determine marketable gas, gas impurities and fuel gas that would be used for processing and transport were estimated and subtracted from the recoverable estimates. Further, certain lower quality areas of the basin were excluded from the assessment, based on a low likelihood of being developed.

549^ Background: The Oncotype DX 21-gene Recurrence Score assay (RS) can potentially predict the magnitude of chemotherapy benefit in patients with stage I-II, node-negative, ER+ disease who will be treated with tamoxifen for 5 years. While use in the United States has grown significantly since its introduction, it is not yet routinely ordered by oncologists in most parts of Canada. The primary purpose of this study was to measure the impact of the Oncotype DX test on the physician’s treatment recommendation in ER+ pN0 breast cancer in British Columbia. Methods: After providing informed consent, patients and medical oncologists completed respective pre-RS questionnaires indicating their treatment preferences and level of confidence and a decisional conflict scale (patients only). At a subsequent visit, after the RS result was known and discussed, the patient and oncologist completed a second set of questionnaires. The proportion of physician treatment recommendations that changed from baseline to follow-up (post RS) were calculated with 95% confidence interval (CI). A prospective health economic (HE) analysis was also performed. Results: From May 2010 to July 2011, two participating BCCA centres enrolled 156 patients. Of the 150 for whom successful RS assay results were obtained, physicians changed their chemotherapy recommendation in 45 cases (30%; 95% CI 22.8-38.0%); either to add (10%; 95% CI 5.7-16.0%) or omit (20%; 95% CI 13.9-27.3%) adjuvant chemotherapy. As a secondary end-point, in 84 cases (56%; 95% CI 47.7-64.1%) there was a change in either the planned chemo and/or endocrine therapy recommendation. There was an overall significant improvement in physician confidence post RS (p < 0.001). Patient decisional conflict also significantly decreased following the RS assay (p < 0.001). The HE analysis is ongoing and will be presented separately. Conclusions: Within the context of a publicly funded health care system, the RS assay significantly affects adjuvant treatment recommendations in ER+ node negative breast cancer, in addition to reducing patient decisional conflict.

No abstract

SPECIAL CLINICS FOR INEBRIATES.* BY JAMES A. DAVIDSON, M.D.CLINICS or bureaux wherealcoholics can be treated as outpatients are well known abroad, but up to now no such clinic